

A European survey to identify new roads for care, training and research around rare metabolic bone diseases

Fernandez I¹, Ahmed SA², Argente J³, Bacchetta J⁴, Bianchi ML⁵, Bianchi, V⁶, Bishop N⁷, Boot AM⁸, Brandi ML⁹, Burren C¹⁰, Cheung M¹¹, Colao AM¹², Coucke P¹³, Davies J¹⁴, Diego de Sotto E¹⁵, Doulgeraki A¹⁶, Gennari L¹⁷, Girschick H¹⁸, Grasemann C¹⁹, Fratzl-Zelman N²⁰, Haeusler G²¹, Hofmann C²², Hogler W²³, Javaid K²⁴, Kant S²⁵, Keen RW²⁶, Kopchak O²⁷, Kost M²⁷, Kostik M²⁷, Mäkitie O²⁸, McDonnell C²⁹, Mantovani G³⁰, Martos Moreno GA³, Mohnike K³¹, Nilsson O³², Oostdijk W²⁵, Padidela R^{33} , Salles JP³⁴, Schnabel D³⁵, Semler O³⁶, Sumnik Z³⁷, Tillmann V³⁸, Turan S³⁹, Shaw N²³, Usardi A¹, Walsh, J⁴⁰. Zillikens C⁴¹ and Linglart A^{1,42}.


^{1.} APHP, Plateforme Expertise Maladies Rares Paris Sud, Paris Sud, France, ^{2.} Glasgow, UK, ^{3.} Madrid, Spain, ^{4.} Lyon, France, ^{5.} Milano, Italy, ^{7.} Sheffield, UK, ^{8.} Gröningen, The Netherlands, ^{9.} Florence, Italy, ^{10.} Bristol, UK, ^{11.}London, UK, ^{12.}Naples, Italy, ^{13.}Ghent, Belgium, ^{14.}Southampton, UK, ^{15.} Balearic Islands, Spain, ^{16.}Athens, Greece, ^{17.}Siena, Italy, ^{18.}Berlin, Germany, ^{19.}Essen, Germany, ^{20.}Vienna, Austria, ^{21.} Vienna, Austria, ^{22.}Wuerzburg, Germany, ^{23.}Birmingham, UK, ^{24.}Oxford, UK, ^{25.}Leiden, The Netherlands, ^{26.}Stanmore, UK, ²⁷. St Petersburg, Russia, ^{28.} Helsinki, Finland, ^{29.}Dublin, Ireland, ^{30.}Milano, Italy, ^{31.}Magdeburg, Germany, ^{32.}Stockholm, Sweden, ^{10.} ^{33.}Manchester, UK, ^{34.}Toulouse, France, ^{35.}Berlin, Germany, ^{36.}Cologne, Germany, ^{37.}Prague, Czech Republic, ^{38.}Tartu, Estonia, ^{39.}Istanbul, Turkey, ^{40.}Sheffield, UK, ^{41.}Rotterdam, The Netherlands, ^{42.}Kremlin-Bicêtre, France.


OBJECTIVES METHODS As expertise in rare or low prevalence complex diseases or conditions is scarce and dispersed, the A google questionnaire based on the operational criteria for European Commission (EC) together with the Member States are working to establish European Healthcare Providers (HCP) published by the European Reference Networks (ERNs) to link existing specialized healthcare providers (1). ERNs will facilitate Commission (2) for the assessment of HCP applicants was access to diagnosis and treatment by centralizing knowledge, experience, medical research, training and sent to the existing networks; the information about the resources in the area of rare or low prevalence complex diseases or conditions. survey was conveyed through the ESPE, ECTS and ESE Rare metabolic bone diseases (RMBD) are at the crossways of Endocrinology, Nephrology, Orthopaedic societies. surgery and Rheumatology. Most of RMBD lead to short stature, bone pain, tooth anomalies, leg This survey consisted of 40 questions covering different

deformities, bone fragility and disability of variable importance. The organization of care varies immensely amongst European countries. The announcement of the future organization of ERNs prompted us to conduct an international survey in order to identify and map the field of expertise, the organization of care and the current activities related to RMBD.

themes such as the description of the local ressources, the organization of care and the capacity to improve diagnosis and care through the development of guidelines and/or databases.


RESULTS





C. Research and

P1-115



% answers

Fig 3: Characteristics of the local support

- A. Medical ressources dedicated to Rare Bone Diseases. Percentage of answers were calculated based on the total number of responses per question
- B. Equipement or technical ressources available for care (not research).

Fig 4 : Practices evaluation (panels A, B, C, D, E and F)

Healthcare professionals were asked to evaluate their practices with patients with RMBD. Pie charts represent the proportion of answers according to the level of implementation for each criterion (3 options were given: fully, partially or not implemented).

CONCLUSIONS

% answers

References

Our survey pointed the needs to 1- improve the visibility of expert centres towards patients and families, caregivers, and European health authorities; 2- guide the transition from child care to adult care; 3harmonize care and enable clinical trials; 4- share the expertise and disseminate the knowledge of RMBD through e-tools and telemedecine. Our survey shows that European networking is a major instrument to improve the standards of care of patients affected with RMBD.

1.Rare Disease policies to improve care for patients in Europe. Rodwell C. & Aymé S. Biochimica and Biophysica Acta Vol. 1852, Issue 10 (2015) 2.http://ec.europa.eu/health/ern/docs/amt_operationalcriteria_healthcareprovi der_en.pdf

Conflict of interest: the authors have no conflict of interest to report.

